Market research
JSPR Jasper Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 22M
- P/E ratio
- Not available
- Analyst target
- 7.375
- Dividend yield
- Not available
- Beta
- 3.04
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US4718712023
- Market cap
- 22M
- P/E ratio
- Not available
- Analyst target
- 7.375
- Dividend yield
- Not available
- Beta
- 3.04
About
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the JSPR discussion.
No comments yet
Start a focused discussion about JSPR.